Pieris Pharmaceuticals, Inc. (PIRS)

11.44 -0.24 (-2.05%) 市場開市。 截至 09:53AM EDT。

Pieris Pharmaceuticals, Inc.

225 Franklin Street
26th Floor
Boston, MA 02110
United States
857 246 8998
https://www.pieris.com

版塊: Healthcare
行業: Biotechnology
全職員工: 46

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Stephen S. Yoder J.D.	CEO, President & Director	774.72k	無	1976
Mr. Thomas Bures	Senior VP, CFO & Treasurer	499.38k	無	1975
Maria Kelman	Executive Director of Investor Relations	無	無	無
Dr. Shane Olwill Ph.D.	Senior VP & Chief Development Officer	無	無	1976
Mr. Prompong Chaikul	Chief Supply Chain Officer	無	無	1987
Dr. Florian Witte Ph.D.	VP and Head of Alliance Management & Early Project Leadership	無	無	無

截止 2022年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Pieris Pharmaceuticals, Inc., a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc.; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies. The company was founded in 2001 and is headquartered in Boston, Massachusetts.

公司管治

截至 無 止，Pieris Pharmaceuticals, Inc. 的 ISS 管治質素評分為 無。 Pillar 分數正在審核中：無；董事會：無；股東權利：無；現金賠償：無。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。